Trade C4 Therapeutics, Inc. - CCCC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.98 |
| Open | 3.93 |
| 1-Year Change | 167.35% |
| Day's Range | 3.93 - 4.28 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | 4.22 | 0.22 | 5.50% | 4.00 | 4.30 | 3.89 |
| Nov 21, 2024 | 3.98 | 0.00 | 0.00% | 3.98 | 4.27 | 3.87 |
| Nov 20, 2024 | 4.02 | -0.12 | -2.90% | 4.14 | 4.14 | 3.81 |
| Nov 19, 2024 | 4.11 | -0.08 | -1.91% | 4.19 | 4.25 | 4.08 |
| Nov 18, 2024 | 4.16 | -0.05 | -1.19% | 4.21 | 4.25 | 3.85 |
| Nov 15, 2024 | 4.28 | -0.46 | -9.70% | 4.74 | 4.75 | 4.20 |
| Nov 14, 2024 | 4.69 | -0.42 | -8.22% | 5.11 | 5.11 | 4.69 |
| Nov 13, 2024 | 5.10 | -0.39 | -7.10% | 5.49 | 5.56 | 5.10 |
| Nov 12, 2024 | 5.48 | -0.30 | -5.19% | 5.78 | 5.86 | 5.37 |
| Nov 11, 2024 | 5.85 | -0.18 | -2.99% | 6.03 | 6.15 | 5.73 |
| Nov 8, 2024 | 6.01 | -0.01 | -0.17% | 6.02 | 6.13 | 5.86 |
| Nov 7, 2024 | 6.00 | 0.04 | 0.67% | 5.96 | 6.20 | 5.87 |
| Nov 6, 2024 | 5.93 | -0.14 | -2.31% | 6.07 | 6.33 | 5.85 |
| Nov 5, 2024 | 6.06 | -0.02 | -0.33% | 6.08 | 6.32 | 5.82 |
| Nov 4, 2024 | 6.41 | 0.93 | 16.97% | 5.48 | 6.49 | 5.38 |
| Nov 1, 2024 | 5.58 | 0.27 | 5.08% | 5.31 | 5.91 | 5.31 |
| Oct 31, 2024 | 5.31 | -0.24 | -4.32% | 5.55 | 5.62 | 5.20 |
| Oct 30, 2024 | 5.50 | -0.26 | -4.51% | 5.76 | 5.86 | 5.49 |
| Oct 29, 2024 | 5.87 | -0.04 | -0.68% | 5.91 | 5.94 | 5.73 |
| Oct 28, 2024 | 5.96 | 0.03 | 0.51% | 5.93 | 6.24 | 5.89 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
C4 Therapeutics, Inc. Company profile
About C4 Therapeutics Inc
C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The Company is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, C4 Therapeutics Inc revenues increased 38% to $45.8M. Net loss increased 26% to $83.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $2.5M to $14M (expense), Research and development - Balancing val increase of 12% to $87.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
490 Arsenal Way
Suite 120
WATERTOWN
MASSACHUSETTS 02472
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com